SCHEMBL2813694

SCHEMBL2813694

COc1ccc(C(=O)Nc2ccc(Cl)c(C(C)(C)CNC(=O)c3nn(C)c4ccccc34)c2)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPT1A P50416 4/20 0.45
MAPT P10636 5/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CPT1B Q92523 2/20 0.44
CPT2 P23786 1/20 0.44
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
NQO2 P16083 1/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
GAA P10253 1/20 0.42
MAPK14 Q16539 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
PDE4D Q08499 1/20 0.42
POLB P06746 3/20 0.42
RXFP1 Q9HBX9 1/20 0.42
KDM4E B2RXH2 2/20 0.42
CACNA1B Q00975 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2816699 0.94 CPT1A (0.45) CPT1AMAPTLMNASMN1; SMN2CPT1B
SCHEMBL2818047 0.90 LCK (0.45) CPT1AMAPTLMNASMN1; SMN2RAB9A
SCHEMBL2816601 0.86 POLB (0.46) CPT1AMAPTLMNASMN1; SMN2RAB9A
SCHEMBL2814896 0.78 HDAC3 (0.46) GAAPOLBKDM4ES1PR1S1PR3
SCHEMBL2818030 0.77 NTRK1 (0.52) MAPTLMNASMN1; SMN2RAB9ANPC1
SCHEMBL2818487 0.75 KDM4E (0.43) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL2819812 0.75 MAPT (0.56) MAPTLMNASMN1; SMN2RAB9ANPC1
SCHEMBL4441630 0.75 CPT1A (0.47) CPT1AMAPTLMNASMN1; SMN2CPT1B
SCHEMBL2816689 0.74 MEN1 (0.53) MAPTLMNARAB9ANPC1MEN1
SCHEMBL2815569 0.73 HDAC3 (0.46) POLBKDM4ES1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2010-09-30 US disclosed
EP-2134676-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE Addex Pharma SA (CH) 2009-12-23 EP disclosed
WO-2008117175-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE FSHR, GNRHR, SHBG CPT1A 4075/4885MAPT 4813/4885LMNA 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.